ClinicalTrials.Veeva

Menu
C

Chase Medical Research, LLC | Waterbury, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Retatrutide
Orforglipron
Bapineuzumab
LY3437943
Finerenone
LY3502970
Empagliflozin
Semaglutide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

29 of 106 total trials

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Enrolling
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Enrolling
Hypertension
Drug: Orforglipron
Drug: Placebo

The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type...

Enrolling
Type 2 Diabetes (T2D)
Drug: Placebo (NNC0487-0111 oral)
Drug: NNC0487-0111 oral

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tol...

Enrolling
Obesity or Overweight
Drug: RO7795081
Drug: Placebo

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Active, not recruiting
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Active, not recruiting
Seasonal Influenza
Biological: Fluarix Tetra
Biological: Fluarix®

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron work...

Not yet enrolling
Osteoarthritis
Drug: Orforglipron
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Active, not recruiting
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight a...

Active, not recruiting
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide,...

Enrolling
Overweight
Obesity
Drug: Tirzepatide
Drug: RO7204239 Matching Placebo

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Enrolling
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: VXA-CoV2-3.3

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these cond...

Enrolling
Hypertension
Cardiovascular Diseases
Drug: Placebo matching Vicadrostat
Drug: Vicadrostat

Trial sponsors

Lilly logo
Pfizer logo
Novo Nordisk logo
Boehringer Ingelheim logo
Bayer logo
Janssen (J&J Innovative Medicine) logo
MannKind logo
Moderna logo
AstraZeneca logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems